Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Struggling with Staying Informed? In the fast-paced world of diagnostic medicine, staying updated with the latest legal, compliance, regulatory, and industry insights is crucial. Yet, finding reliable and comprehensive information can be overwhelming and time-consuming.
Lab Industry Advisor to the Rescue! Lab Industry Advisor provides comprehensive, up-to-date insights and analyses tailored to your needs. With expert commentary and actionable advice, you’ll stay ahead of the curve. No more sifting through endless sources—everything you need is right here!
Start your free trial today and see how Lab Industry Advisor can transform your approach. Get instant access to invaluable resources designed to keep you informed and competitive. Explore detailed reports, in-depth articles, and exclusive industry insights that help you make better decisions faster. Choose from three subscription levels tailored to fit your needs: Essential, Premium, and Elite.
Additional Business Intelligence Offerings
Clinical Diagnostics Insider
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Virtual Events & Webinars
Virtual events & webinars offer a variety of solutions and strategies for dealing with key issues labs face.
Lab Industry Advisor Subscriptions Include
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
CMS Slated to Close Change Healthcare Payment Program
Program meant to ease cash flow disruptions experienced by some Medicare providers and suppliers due to the cyberattack will conclude in mid-July
Staying on Top of Medical Necessity and Marketer Compliance
Recent enforcement actions show that clinical laboratories must remain vigilant about compliance relating to these areas
Pandemics: Prediction, Prevention, and Response
Recent efforts to forecast the next infectious disease outbreak and steps labs can take to ensure they’re prepared.
Sepsis: Diagnosis on a Deadline
New molecular tests and diagnostic support technologies can help labs detect sepsis earlier, faster, and with greater accuracy
Expert Q&A: Lessons Learned from a Total Laboratory Automation Project
Clinical Microbiology division head Jeff Fuller, FCCM, discusses his clinical laboratory’s recent automation transformation and offers tips to ensure success
CDC Releases Recommendations to Address Rising Syphilis Cases
Key updates from the CDC’s new lab recommendations for syphilis testing.
A Debate—Resolved: Immunohistochemistry Should Be Regulated As An Assay
Join G2 Intelligence for this interactive discussion about whether clinical immunohistochemistry testing should be a stain or an assay, with our experts offering arguments for and against the proposed changes
Lab Institute Virtual Event: Finding Opportunities to Maximize Efficiency
Our event provides lab leaders with strategies to boost their lab's efficiency and improve their organization's bottom line
FDA Watch: New Test for Esophageal Conditions is Coming to the US
UK-developed assay that uses a sponge appears to reduce the need for more invasive endoscopies.
Dx Deals: Quest and Labcorp Move beyond Laboratory Testing
Both companies have made recent moves to diversify further.
Diagnostics Pipeline: More AI-Reliant Platforms Being Approved by the FDA
Such assays rely more on imaging and computer power than tissue samples to make diagnoses.
